Overview
Dihexa is an oligopeptide derived from angiotensin IV that was developed at Washington State University by Joseph Harding and colleagues. It is notable for being approximately 10 million times more potent than BDNF at promoting neuronal connectivity. Dihexa enhances cognitive function, promotes new synapse formation, and is being investigated as a potential treatment for Alzheimer's disease and other neurodegenerative conditions.
Mechanism of action
Dihexa binds to hepatocyte growth factor (HGF) and its receptor c-Met, potentiating the HGF/c-Met signaling pathway which is critical for neuronal survival, neurite outgrowth, and synaptogenesis. It stabilizes the HGF dimer and enhances receptor dimerization, amplifying downstream signaling through PI3K/Akt and MAPK/ERK pathways. This promotes formation of new synaptic connections (spinogenesis) at concentrations 7 orders of magnitude lower than BDNF itself.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| cognitive enhancement | oral | 10–30 mg | daily | One of the few peptides with oral bioavailability. Start at low dose. Limited human dosing data — extrapolated from animal studies. Use with caution. |
| cognitive enhancement | subcutaneous | 5–20 mg | daily | Subcutaneous offers more consistent dosing. Limited human experience. Short cycles (2-4 weeks) recommended. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Harding et al. demonstrated that Dihexa restored cognitive function in aged rats to levels comparable to young animals. It crossed the blood-brain barrier when administered orally or subcutaneously. Studies showed reversal of scopolamine-induced cognitive deficits and improvement in spatial learning (Morris water maze). Patent filed for Alzheimer's disease treatment (US Patent 8,710,016). No human clinical trials completed. The extraordinary potency raises both excitement and caution in the research community.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Dihexa for synergistic effects.
Legal status
Not FDA-approved. Research chemical with a patent for neurological applications. Not scheduled. Limited availability compared to more established peptides.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings.